STOCKHOLM – April 10, 2017 – A consortium including ContextVision, a medical technology company specializing in image analysis and artificial intelligence, received a support grant of SEK 500 000 from the Swedish government-funded innovation agency, Vinnova.
The project serves to evaluate if deep learning can provide a more exact and more reliable analysis of the images than visual inspection. The research will focus on a well-defined group of cancer patients where PET/CT-images of before and after treatments as well as follow-ups are available.
The consortium includes the two prestigious institutions: the Royal Institute of Technology and the Karolinska Institute; as well as two commercial partners: Electa AB and ContextVision AB.
“This is a very prominent group of skilled researchers and we are proud to be chosen as a close research partner for this project,” said Anita Tollstadius, CEO of ContextVision.
Advanced analysis with deep learning will be implemented through a close collaboration within the consortium, with Contextvision as expert advisors in deep learning technology. Clinical data will be used to develop algorithms that can predict survival and cure.
ContextVision has developed an expertise within deep learning, the latest technology within artificial intelligence, and uses the technology for the creation of new, innovative products that have the potential to improve healthcare.
For more information, visit www.contextvision.com.
ContextVision is a medical technology company specializing in image analysis and artificial intelligence. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment. As an industry pioneer for more than 30 years, ContextVision is taking a leading position within deep learning, the latest artificial intelligence technology. ContextVision is currently investing significantly in the field to expand its product portfolio. The present product portfolio includes state-of-the-art image enhancement software for 2D/3D/4D ultrasound, MRI, X-ray and mammography which is used by leading equipment manufacturers worldwide. ContextVision is based in Sweden and listed on the Oslo Stock Exchange under the ticker COV. For more information, please visit www.contextvision.com.